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Abstract
Background: Insulin resistance is a strong predictor of the development of type 2 diabetes mellitus. Chronic
helminth infections might protect against insulin resistance via a caloric restriction state and indirectly via T-helper-2
polarization of the immune system. Therefore the elimination of helminths might remove this beneficial effect on
insulin resistance.
Methods/Design: To determine whether soil-transmitted helminth infections are associated with a better whole-body
insulin sensitivity and whether this protection is reversible by anthelmintic treatment, a household-based
cluster-randomized, double blind, placebo-controlled trial was conducted in the area of Nangapanda on Flores
Island, Indonesia, an area endemic for soil-transmitted helminth infections. The trial incorporates three monthly
treatment with albendazole or matching placebo for one year, whereby each treatment round consists of
three consecutive days of supervised drug intake. The presence of soil-transmitted helminths will be evaluated
in faeces using microscopy and/or PCR. The primary outcome of the study will be changes in insulin resistance as
assessed by HOMA-IR, while the secondary outcomes will be changes in body mass index, waist circumference, fasting
blood glucose, 2 h-glucose levels after oral glucose tolerance test, HbA1c, serum lipid levels, immunological parameters,
and efficacy of anthelmintic treatment.
Discussion: The study will provide data on the effect of helminth infections on insulin resistance. It will assess the
relationship between helminth infection status and immune responses as well as metabolic parameters, allowing the
establishment of a link between inflammation and whole-body metabolic homeostasis. In addition, it will give
information on anthelmintic treatment efficacy and effectiveness.
Trial registration: This study has been approved by the ethical committee of Faculty of Medicine Universitas
Indonesia (ref: 549/H2.F1/ETIK/2013), and has been filed by the ethics committee of Leiden University Medical
Center, clinical trial number: ISRCTN75636394. The study is reported in accordance with the CONSORT
guidelines for cluster-randomised trials.
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Background
The number of people with diabetes mellitus is increasing
worldwide [1-3]. At present, 8.3% of adults (382 million
people) have diabetes mellitus [4] and Asia is a major site
of this rapidly emerging epidemic [5]. In many Asian
countries, including Indonesia, rapid socio-economic de-
velopment has led to a shift in infrastructure, technology
and introduction of Western style diets, which promotes
overnutrition and sedentary lifestyles [5-8]. These changes
have already led to an increasing prevalence of diabetes
mellitus in Indonesia [9-12].
A strong predictor for the development of type 2 dia-
betes mellitus (DM2) is insulin resistance [13,14], which
is caused by complex disturbances in multiple biological
systems. There is now abundant evidence that inflamma-
tion [15] plays a role in the development of DM2, in
addition to the more established relationship between an
altered energy balance resulting from excess consumption
of high-energy foods and/or decreased physical activity. In
DM2 subjects, chronic low-grade inflammation is a com-
mon feature [15] which results, at least in part, from the
activation of inflammatory pathways by fatty acids in mul-
tiple organs [16-18]. However, the fundamental molecular
mechanisms are still incompletely understood [19].
In developing countries, infectious pressure might be
one particular modifier of insulin resistance. Helminth
infections, which are still endemic in many low to mid-
dle income countries, may therefore affect whole-body
and tissue-specific insulin sensitivity owing to their im-
munomodulatory properties [20]. Previous studies have
shown that helminth infections can adopt an immune
evasion strategy by inducing regulatory T cells [21-26].
Hereby helminth infections may decrease systemic inflam-
mation and subsequently the development of inflamma-
tory diseases, including DM2 [27-30]. Studies examining
the relationship between helminth infections and DM2 in
both humans [31,32] and murine models [33,34] support
this hypothesis. At a molecular level, mTOR, a serine/
threonine protein kinase located downstream of insulin
signalling, plays an essential role in immune cell energy
metabolism and function [35,36]. Furthermore, it has been
shown that STAT6 signalling downstream of IL-4, as well
as Th2 responses induced by helminths, improve glucose
metabolism and insulin signalling [33,37]. Intriguingly, in
humans, immune intervention with IL-1 receptor antag-
onist (Anakinra) has also been shown to influence glucose
metabolism [38].
Helminths are also known to reduce energy intake and
thereby change the energy balance [39], which may be
beneficial in terms of insulin resistance [39,40]. Helminths
may therefore both directly improve insulin sensitivity via
a caloric restriction state and indirectly via Th2 activation.
It appears, the immune system which has evolved with
helminths [41] and under conditions of low energy intake,
seems to be out of balance in situations of nutritional
overload and decreasing exposure to parasites [23,42]. In
line with the proposed beneficial effects of helminth infec-
tions on glucose metabolism, our previous unpublished
cross sectional study in Flores Island, Indonesia, has
shown that subjects infected with intestinal helminths
have a significantly lower insulin resistance as expressed
by HOMA-IR.
Although aforementioned studies strongly suggest that
there is an association between helminth infections, sys-
temic inflammation and glucose metabolism, the causality
in these relationships has not been demonstrated as yet.
Therefore we have initiated a large scale cluster random-
ized controlled trial (RCT) with the aim to assess the ef-
fect of anthelmintic treatment on insulin resistance, the
hypothesis being that reduction of worm load to undetect-
able levels will lead to a higher degree of insulin resistance.
While study outcomes will be analysed at the individual
participant level, a household cluster randomization was
chosen to minimise contamination between treatment
groups and therefore reinfection of treated individuals.
Study design
Study area
The study area is located in Nangapanda, a sub-district
of the Ende District of Flores Island, Indonesia [43,44].
Nangapanda is a semi-urban coastal area with a popula-
tion of approximately 22.000 people being divided over 29
villages. Our study area includes three of these villages
(Ndeturea, Ndorurea 1, Ndorurea), with a total population
of 3698 people, from which most of the adult population
are farmers. Previous studies have shown that this area
is endemic for soil-transmitted helminth (STH) infec-
tions [45]. A detailed map of the study area has been
published [43].
Trial design
The study is designed as a household-based cluster-
randomized, double-blind trial with two arms. In one
arm treatment is given with albendazole (single dose of
400 mg) on 3 consecutive days, while the other arm con-
sists of matching placebo treatment (both albendazole and
placebo are manufactured by PT Indofarma Pharmaceut-
ical, Bandung, Indonesia). The treatment is provided every
three months for a period of 1 year (total 4 rounds) to all
household members except children below 2 years of age,
while subjects aged 16 and above will undergo clinical and
laboratory examination. Subjects with active treatment for
diabetes mellitus, serious concomitant disease and preg-
nancy will be excluded.
The population was randomised by JWAS and JJH using
computer aided block randomization at household level,
utilizing Random Allocation Software to assign treatment
groups. Both study investigators and patients are blinded
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for treatment codes. The treatment code will be unblinded
when all data needed for analysis are cleaned and entered
into the database. An additional randomization was per-
formed in a subgroup of individuals, who will undergo an
oral glucose tolerance test and immunological studies in
order to study glucose metabolism and immune mecha-
nisms in more detail. For this subgroup, we aimed to select
one subject per household and stratified by age group (16–
36 years of age, 36–56 years of age, and >56 years of age)
to ensure that sufficient numbers of all age groups are par-
ticipating. Randomization was based on households.
Well trained community workers were recruited and
trained to distribute the drugs. These workers were also
trained to assist during clinical examination and sample
collection and were involved in health promotion within
the population. Community workers and research team
members will directly supervise the study participants
while taking the study medication, and will collect empty
drug canisters at each visit to confirm compliance. Fur-
thermore, assessment of side effects will take place during
these visits and migration and death will be noted. Ad-
verse events spontaneously reported by the patient or ob-
served by the investigators, will be monitored throughout
the study. After completion of the study, the whole study
population will be treated with a single dose of albenda-
zole (400 mg) for 3 consecutive days.
Outcomes
As this study aims to assess the effect of anthelmintic
treatment on whole-body insulin sensitivity, our primary
outcome is a change in insulin resistance as assessed by
HOMA-IR between both treatment arms after one year of
treatment. Secondary outcomes are changes in body mass
index and waist circumference, fasting blood glucose,
2 h-glucose levels after oral glucose tolerance test, HbA1c,
serum lipid levels, immunological parameters, and efficacy
of anthelmintic treatment.
Sample size
Sample size is calculated according to intention to treat
analysis in which we will need 1580 subjects in total.
Based on our previous study [45] we assume that the aver-
age household size is 4 and that around 20% will be lost to
follow up after one year. We use a significance level of
5% and a power of 80%. Correlations within house-
holds are taken into account by using the correction fac-
tor 1 + (m-1) ICC, with m being the household size and
ICC the intra-class correlation. The sample size is com-
puted for a difference in mean between the two treatment
groups of 0.18 and an ICC of 0.1.
For the subgroup of individuals undergoing an oral
glucose tolerance test, a sample size of 335 subjects in
total is calculated assuming that around 20% will be lost
to follow up after one year and using a significance level
of 5% and a power of 80%. The sample size is computed
for a difference in mean of 10.3 mg/dL and a standard
deviation of glucose level of 30 mg/dL.
Methods
Sample collection
At baseline all eligible subjects, aged 16 and above will
be invited to visit the examination centre after an over-
night fasting and to provide stool, blood and first morning
urine samples. During this visit, participant’s education
level and profession will be registered. After 1 year of
treatment follow-up sample collection will take place as
shown in Table 1.
Clinical anthropometry assessment
Anthropometric measurements of body weight, height,
waist and hip circumference are obtained using the
National Heart, Lung, and Blood Institute (NHLBI) prac-
tical guidelines. To measure body weight a flat scale for
mobile use (SECA Model 876, Seca Gmbh Co, Hamburg,
Germany) is used, while a portable stadiometer (SECA
Model 213, Seca Gmbh Co, Hamburg, Germany) is used
to measure height. Waist and hip circumference are mea-
sured using ergonomic circumference measuring tape
(SECA Model 201, Seca Gmbh Co, Hamburg, Germany).
In addition, body fat composition is measured using a
Tanita body composition analyser (TBF-300A, Tanita Corp,
Tokyo, Japan). Three blood pressure measurements (left
arm, sitting upright position, after resting 5 minutes) are
taken from each subject, using a digital sphygmoman-
ometer (HEM-7200, Omron Healthcare Co, Ltd, Kyoto,
Japan), and calibrated using a Riester nova-presameterH-
Desk model mercury sphygmomanometer (Gerhard Glufke
Rudolf Riester GmbH & Co, Jungingen, Germany) and a
3MTM LittmannH Classic II S.E. Stethoscope (3 M, St.
Paul, Minnesota, USA). The average of three systolic/
diastolic blood pressure measurements will be used
for analysis.
Parasitological examination
To assess intestinal helminth infection, stool containers
are distributed and collected by health workers. Stool
samples are examined by the Kato Katz method [46] for
Table 1 Study schedule of the Sugarspin project
Outcome Baseline 3 monthly treatment 1 year
follow up1st 2nd 3rd 4th
Clinical Anthropometry X X
Parasitological examination X X
Metabolic parameters X X
Immunological parameters X X
Assessment of side effects X X X X X
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identification and quantification of STH eggs using 2
slides for each sample. An aliquot of the fresh stool
samples is frozen at −20°C in the field and subsequently
at −80°C in laboratories of the Departments of Parasitology
at Leiden University Medical Center, Leiden, The Netherlands
and Faculty of Medicine Universitas Indonesia, Jakarta,
Indonesia for DNA extraction [43]. Part of the stool
sample will be saved for potential future analysis of the
microbiome.
DNA isolation and helminth real-time PCR
DNA isolation from stool will be performed as described
elsewhere [43], with some minor modifications. Real-
time PCR will be performed to detect the presence of A.
duodenale, N. americanus (hookworm), A. lumbricoides
and T. trichiura using a method described previously
[43] with some modifications.
Blood collection
Peripheral blood is collected into EDTA and SST Vacutainers
(BD, Franklin Lakes, NJ, USA). Giemsa-stained peripheral
blood smear is prepared to evaluate neutrophil and eo-
sinophil counts. In a subset of the study population, add-
itional blood is collected in PAXgene Blood RNA Tubes
(PreAnalytiX GmbH, Hombrechtikon, Switzerland) and
Sodium Heparin Vacutainers (BD). Blood collected in
PAXgene Blood RNA Tubes will be used to study RNA
expression profiles, while blood collected in Sodium Hep-
arin Vacutainers will be used for detailed immunological
measurements as described below (section Immunological
methods). All samples deriving from EDTA and SST
Vacutainers (serum, plasma, cell pellet and whole blood)
and all PAXgene Blood RNA Tubes are kept at −20°C at
the Field Clinical Research Centre (FCRC) and will be sent
on dry ice to the University’s laboratory for storage at −80°C.
Metabolic parameters
Fasting blood glucose is measured in capillary blood
using Breeze®2 glucose meters (Bayer Health Care LLC,
Basel, Switzerland). An oral glucose tolerance test is per-
formed in a subset of the study population according to
the WHO protocol [47,48]. Glucose levels are measured in
capillary blood using Breeze®2 glucose meters after over-
night fasting and 2 hours after ingesting 75 g of anhydrous
glucose dissolved in 200 cc of water. Insulin, HbA1c and
lipid profiles will be measured in an internationally accre-
dited laboratory. HOMA-IR, a well-validated measure of
insulin resistance will be calculated to estimate insulin re-
sistance [49].
Immunological methods
The immunological parameters that will be studied are
1) Total IgE levels as one of the markers of a Th2 re-
sponse and its relation to metabolic parameters, 2)
Circulating pro- and anti-inflammatory cytokines in
order to study their relationship to metabolic parameters,
3) Antigen specific IgE and IgG to Ascaris lumbricoides to
monitor antibody responses to one of the helminths stud-
ied as a marker of changing immune responses as a result
of anthelmintic treatment, 4) Granulocyte (neutrophil and
eosinophil) frequencies and their activation to assess
whether granulocytes, in particular eosinophils which are
associated with Th2 response, are linked to helminth in-
fections and metabolic parameters, 5) Peripheral blood
mononuclear cells (PBMC) subset analysis and polarisa-
tion by flow cytometry in order to assess the relationship
between immune cell frequencies (T cell subsets, B cell
subsets, monocyte subsets, NK cells and myeloid suppres-
sor cells) in situ as well as after activation and metabolic
parameters.
Total IgE
Total IgE will be measured using ELISA with rabbit
anti-human IgE antibodies (Dako, Glostrup, Denmark)
and goat anti-human IgE biotinylated antibodies (Vector
Laboratories, Burlingame, CA, USA) as capture and de-
tection antibodies, as described previously [43]. The
World Health Organization standard of human serum IgE
was used as a reference (National Institute for Biological
Standards and Control). The results will be expressed in
International Units (IU).
Circulating cytokines
Pro and anti-inflammatory cytokines (TNFα, IFNγ, IL-1,
IL-6, IL-10, TGFβ) will be measured in serum samples
using cytokine kits with high sensitivity.
Ascaris-specific IgE
Ascaris antigen will be prepared from Ascaris lumbri-
coides worms as described previously [50]. Maxisorp
plates (Thermo Fisher Scientific, Roskilde, Denmark)
will be coated overnight with 5 μg/ml Ascaris antigen in
0.1 M carbonate buffer (pH 9.6). Plates will be blocked
for 1 hour with PBS containing 2% bovine serum albu-
min. Samples will be diluted 1/60 in 0.1 M Tris–HCl
containing 0.05% Tween-20 and incubated overnight to-
gether with a pool of positive standard plasma contain-
ing 1 × 106 arbitrary units (AU) parasite specific IgE.
After a washing step, goat anti-human IgE biotinyl-
ated antibodies (Vector) will be incubated followed by
streptavidin-HRP (Sanquin, Amsterdam, the Netherlands).
The color is developed by adding 3,3′,5,5′ tetramethylben-
zidine (TMB) (KPL, Gaithersburg, MD, USA). The re-
action will be stopped by adding 1.8 M H2SO4 and
absorbance will be read at 450 nm in an automated
plate reader.
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Ascaris-specific IgG isotypes
Maxisorp plates will be coated with Ascaris antigen as
described for Ascaris specific IgE above. Blocking will be
done using PBS containing 5% bovine serum albumin.
Samples will be diluted 1/1000, 1/10, 1/5 or 1/25 for
IgG1, IgG2, IgG3 and IgG4 respectively, and a pool of
positive standard plasma containing 1 × 106 arbitrary
units (AU) parasite specific IgG isotypes will be included
in each plate. After overnight incubation, HRP-labelled
anti human IgG isotypes (Sanquin) in PBS 0.05% Tween-
20 will be added for 4 hours incubation at 37°C using the
following dilutions: 1/3000 for anti IgG1 (HP6188) and
anti IgG4 (HP6196); 1/1000 for anti IgG2 (HP6014) and
anti IgG3 (HP6095). TMB substrate will be used to de-
velop the color and the reaction will be stopped as de-
scribed above.
Whole blood stimulation and fixed granulocyte
cryopreservation
To study the expression of activation markers on granu-
locytes, 600 μl of heparinised venous blood is divided
over 3 polystyrene tubes (200 μl/tube). After a pre-
incubation of 5 minutes in a 37°C waterbath, a 5 minutes
stimulation at 37°C is performed with N-Formyl-Met-
Leu-Phe (FMLP, 10−5 M; Sigma, Saint Louis, MO, USA)
or eotaxin (10−7 M; R&D systems, Abingdon, UK). Sub-
sequently, 4 ml of FACS lysing solution (BD) is added
and after an incubation period of 15 minutes at room
temperature the red blood cells is lysed while white
blood cells, including granulocytes, become fixed. Cells
are washed with RPMI 1640 containing 10% heat-
inactivated FCS and then resuspended in RPMI 1640
containing 10% of heat-inactivated foetal calf serum
(FCS) and 10% dimethyl sulfoxyde (DMSO). Cryovials
containing the cell suspension are placed at −80°C for
minimum of 4 hours, followed by storage in liquid nitro-
gen until analysis.
PBMC cryopreservation
Peripheral blood mononuclear cells (PBMCs) are iso-
lated from heparinised venous blood using Ficoll density
gradient centrifugation within 12 hours after blood collec-
tion. After isolation, cells are cryopreserved in RPMI 1640
containing 20% of heat-inactivated foetal calf serum (FCS)
and 10% dimethyl sulfoxyde (DMSO). Cryovials contain-
ing the cell suspension are transferred to a freezing unit
which is placed in a −80°C freezer for minimum of 4 hours.
Subsequently, vials are stored in liquid nitrogen until
analysis.
Metabolomics for metabolic profiling
Urine samples and blood samples from heparinized
blood are kept at −20°C at the FCRC and subsequently
stored at −80°C at the University's laboratory for future
metabolomics measurements. The exploratory metabo-
lomics analysis will be performed by 1H-NMR and LC-
MS metabolomics, a combination of NMR and LC-MS
proposed for this study provides a comprehensive cover-
age of metabolome and as such increase the probability
Figure 1 Flow diagram of the Sugarspin project.
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of finding physiologically meaningful associations within
the data.
Data management and statistical analyses
A centrally accessible database designed in Microsoft
Access is established and the data is entered by well-trained
data entry personnel. Descriptive data will be summarized
for continuous variables as mean +/− SD for normally
distributed data and median (range) for non-normally
distributed data. Categorical data will be expressed as
proportions.
The effect of anthelmintic treatment on insulin resist-
ance (HOMA-IR) as our primary outcome will be assessed
using an intention to treat approach after 1 year of treat-
ment using mixed models to account for the correl-
ation within households, in which relevant confounders
B
A
Figure 2 Age pyramid. Age pyramid of all individuals living in the study area in Nangapanda, Flores Island, Indonesia (n = 3698 subjects, 52%
female) (A), and of study participants (n = 1669 subjects, 60% female) (B).
Figure 3 Job distribution. At baseline, profession was assessed for study participants (n = 1669 subjects).
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(including age, gender, BMI, village) are entered. The
characterization of immune responses to helminth infec-
tions and systemic inflammation will be assessed by meas-
uring cytokine profiles. Moreover, for these analyses
multilevel modelling will be used and the use of longitu-
dinal data will take repeated measurement into account
[51]. The mediation of helminth’s effects on insulin resist-
ance via immune responses will also be assessed.
Ethical approval, trial registration and consent
This study has been approved by The Health Research
Ethical Committee, Faculty of Medicine, Universitas
Indonesia Cipto Mangunkusumo Hospital, Jakarta,
Indonesia (reference number:549/H2.F1/ETIK/2013). It
has also been filed by the ethics committee of Leiden
University Medical Center and is registered as a clinical
trial ref: ISRCTN75636394 (http://www.isrctn.com/
ISRCTN75636394). The local health authorities have
been informed about this study and have given their
approval and support. The study, its benefits and risks are
explained to the population and consent forms are distrib-
uted to be signed by the subjects who are willing to par-
ticipate in this study. They are informed that they can
withdraw from the study at any time, for any reasons and
without any consequences.
Description of the population recruited
So far, the study has provided the following data (Figure 1).
At baseline, a total of 3698 individuals were registered
in 752 households. Of the 2428 subjects aged 16 years
or older, 1669 subjects were eligible with consent for
examination. For the oral glucose tolerance test and
immunological studies 339 subjects were randomly se-
lected and gave approval.
Figure 2 shows the age pyramid of both the total
population in the study area and the study population.
In the study population farming and fishing are the trad-
itional source of income while some individuals engage
in jobs at government offices or in the private sector
(Figure 3), a similar distribution is seen in the total
population. The education level of the majority of sub-
jects in the study population is elementary school (33%),
followed by senior high school (22%), and junior high
school (16%), while 11% has college or university de-
grees. Moreover, 18% of the subjects is illiterate, either
not educated at all or dropped out from elementary
school (Figure 4). A similar distribution of the education
level is seen in the total population.
Discussion
The SUGARSPIN trial is the first and currently the only
longitudinal study investigating the effects of anthelmintic
treatment on whole-body insulin sensitivity. This placebo-
controlled trial enables us for the first time to investigate
the causal relationship between helminth infections, sys-
temic inflammation and glucose metabolism in humans.
In addition, this study will provide data on anthelmintic
treatment efficacy and effectiveness in a large population
in a developing country like Indonesia.
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